Immunomodulatory effects of the alkaloid sinomenine in the high responder ACI-to-Lewis cardiac allograft model

被引:49
作者
Candinas, D
Mark, W
Kaever, V
Miyatake, T
Koyamada, N
Hechenleitner, P
Hancock, WW
机构
[1] HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, SANDOZ CTR IMMUNOBIOL, BOSTON, MA 02215 USA
[2] UNIV ZURICH HOSP, DEPT SURG, CH-8091 ZURICH, SWITZERLAND
[3] UNIV INNSBRUCK HOSP, DEPT SURG, A-6020 INNSBRUCK, AUSTRIA
[4] HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02215 USA
[5] HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, CTR IMMUNOBIOL, BOSTON, MA 02215 USA
[6] HANNOVER MED SCH, INST MOL PHARMACOL, D-30623 HANNOVER, GERMANY
[7] HARVARD UNIV, NEW ENGLAND DEACONESS HOSP, SCH MED, DEPT PATHOL, BOSTON, MA 02215 USA
关键词
D O I
10.1097/00007890-199612270-00030
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Extracts of the plant Sinomenium acutum have been used safely since ancient times in Chinese medicine for treatment of rheumatic diseases, and the purified alkaloid, sinomenine, was recently shown to have anti-inflammatory and antirheumatic effects. This study describes the effects of sinomenine in the high responder ACI-->Lewis cardiac transplant model in which allograft rejection occurred at 5 days posttransplant. Treatment with sinomenine (15-30 mg/kg/day i.p.) or a subtherapeutic dose of cyclosporine (CsA, 1.5 mg/kg/day, i.m.) prolonged allograft survival only marginally (mean survival 5.4 and 7.8 days, respectively). In contrast, the combination of sinomenine and CsA had a statistically significant synergistic effect, with a mean survival of 42.2 days (P < 0.001). Allografts harvested at day 5 from recipients treated with either sinomenine or CsA showed dense mononuclear cell infiltrates with widespread subepicardial infarcts, edema, and microvascular platelet and fibrin deposition. Immunohistologic analysis showed that intragraft leukocytes consisted of >75% macrophages with similar to 10-20%) and labeling for IL-2 (similar to 10%), and IFN-gamma (10-20%), as well as TNF-alpha (>50%) and iNOS (>50%), but only low levels of IL-4 or IL-10 (<5%). Intragraft endothelial cells were activated, as shown by upregulated of MHC class II antigen and ICAM-1 (CD54) compared with only basal levels in normal donors hearts. Combined sinomenine/CsA therapy significantly enhanced graft morphology, resulting in only mild mononuclear cell infiltration, and an absence of infarcts, platelets, or fibrin deposition. Though residual intragraft mononuclear cells at day 5, as in control grafts, consisted primarily of macrophages plus small numbers of IL-2R+ T cells, these cells lacked expression of IL-2, had only low levels of IFN-gamma, but showed dense labeling for IL-4 and IL-10. In addition, TNF-alpha and iNOS were reduced to basal levels and no endothelial cell activation was observed, despite high titers of endothelium-bound IgM, IgG, and C3. Mitogen-induced in vitro proliferation of rat thymocytes was also more effectively decreased by the sinomenine/CsA combination than by either agent alone. These studies demonstrate the therapeutic value of sinomenine in transplantation, and indicate that this agent has novel and interesting antimacrophage, T cell and endothelial effects that warrant further evaluation.
引用
收藏
页码:1855 / 1860
页数:6
相关论文
共 21 条
[1]  
BUDAVARI S, 1989, MERCK INDEX, P1352
[2]  
CARR DJJ, 1995, ADV EXP MED BIOL, V373, P131
[3]  
FECHO K, 1994, J IMMUNOL, V152, P5845
[4]  
Feng C I, 1965, Yao Xue Xue Bao, V12, P492
[5]  
HANCOCK WW, 1994, AM J PATHOL, V144, P1149
[6]   ORAL, BUT NOT INTRAVENOUS, ALLOANTIGEN PREVENTS ACCELERATED ALLOGRAFT-REJECTION BY SELECTIVE INTRAGRAFT TH2 CELL ACTIVATION [J].
HANCOCK, WW ;
SAYEGH, MH ;
KWOK, CA ;
WEINER, HL ;
CARPENTER, CB .
TRANSPLANTATION, 1993, 55 (05) :1112-1118
[7]   EFFECT OF SINOMENINE ON ANTIBODY-RESPONSES IN MICE [J].
HOJO, H ;
KONDO, Y ;
UMEDA, H ;
TAHIRA, T ;
HASHIMOTO, Y .
JOURNAL OF IMMUNOPHARMACOLOGY, 1985, 7 (01) :33-42
[8]  
IRINO S, 1958, ACTA MED OKAYAMA, V12, P53
[9]  
KAEVER V, 1995, P 9 INT C IMM SAN FR, P5084
[10]  
Ke XY, 1986, BEIJING YIXUE, V3, P186